With shares of Corning (NYSE:GLW) trading around $17, is GLW an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework.
T = Trends for a Stock’s MovementCorning produces and sells specialty glasses, ceramics, and related materials worldwide. It operates in five segments: Display Technologies, Telecommunications, Environmental Technologies, Specialty Materials, and Life Sciences. Corning has launched Corning Lotus Glass, an environmentally friendly display glass for organic LED and LCD displays that are used in portable devices such as smartphones, tablets, and notebook computers. Smart phones, tablets, notebook computers, and their related materials are seeing explosive growth in developed and developing countries around the world.
Samsung Electronics���(SSNLF.PK)�purchase of Corning shares and a glass supply agreement between the two companies will last until 2023. Samsung Display is buying $2.3 billion worth of shares in Corning, according to a statement from Corning, making Samsung�� combined stake in Corning 7.4 percent. The Samsung purchase is expected to close in the first quarter of 2014.
Hot Airline Stocks To Buy Right Now: Stericycle Inc (SRCL)
Stericycle, Inc., incorporated on March 21, 1989, is in the business of managing regulated waste and providing an array of related and complementary services. The Company operates in the United States, Argentina, Brazil, Canada, Chile, Ireland, Japan, Mexico, Portugal, Romania, Spain, and the United Kingdom. The regulated waste services the Company provides include medical waste disposal, its Steri-Safe medical waste and compliance program, its Clinical Services program, its Bio Systems reusable sharps disposal management services, pharmaceutical waste disposal, and hazardous waste disposal. In addition to the Company's regulated waste services, the Company offers regulated recall and returns management services, patient communication services, and medical safety products. The Company's regulated recall and returns management services consist of a number of solutions for a variety of businesses but consist primarily of managing the recall, withdrawal or return of expired or recalled products and pharmaceuticals. During the year ended December 31, 2012, it completed 41 acquisitions, of which 17 were domestic businesses and 24 were international businesses in Latin America, Europe, and Japan. In August 2013, Stericycle Inc acquired Eclipse Marketing.
The Company also provides communication services to healthcare providers to improve office productivity and communications with patients. As of December 31, 2012, the Company's worldwide networks included a total of 153 processing facilities, 141 transfer sites, and 64 recall and returns or communication services facilities. The Company serves approximately 541,000 customers worldwide, of which approximately 16,500 are large-quantity generators, such as hospitals, blood banks and pharmaceutical manufacturers, and approximately 524,500 are small-quantity generators, such as outpatient clinics, medical and dental offices, long-term and sub-acute care facilities, veterinary offices, municipalities and retail pharmacies. For large-quantity generat! ors of regulated waste such as hospitals and for pharmaceutical companies and distributors, the Company offers its regulated waste management services; its Bio Systems reusable sharps disposal management services; its pharmaceutical waste services; its Integrated Waste Stream Solutions (IWSS) program; a variety of products and services for infection control; its regulated recall and returns management services for expired or recalled products and pharmaceuticals, and variety of patient communication services. For small-quantity generators of regulated waste such as doctors' offices or retail pharmacies, the Company offers its Steri-Safe OSHA, HIPAA compliance, and clinical services programs.
The Company supplies specially designed reusable leak-resistant and puncture-resistant plastic containers to most of its large-quantity customers and many of its larger small-quantity customers. The Company collects containers or corrugated boxes of regulated waste from its customers depending upon customer requirements, contract terms and volume of waste generated. The waste is then transported directly to one of the Company's processing facilities or to one of its transfer stations where it is combined with other regulated waste and transported to a processing facility. The Company collects some expired or recalled products, but more typically, customer ships them directly to its processing facilities. Upon arrival at a processing facility, containers or boxes of regulated waste are typically scanned to verify that they do not contain any unacceptable substances like radioactive material. The regulated waste is then processed using one of the Company's various treatment or processing technologies. Upon completion of the particular process, the resulting waste or incinerator ash is transported for resource recovery, recycling or disposal in a landfill owned by an unaffiliated third party. The Company provides complete documentation to its customers for all regulated waste that the Company collect in ac! cordance ! with applicable regulations and customer requirements.
Advisors' Opinion:- [By WWW.GURUFOCUS.COM]
Stericycle (SRCL) alone operates globally and generates close to $2 billion in annual revenues. Despite Stericycle's strong business performance during the recently reported quarter, the stock detracted from performance, partially driven by headlines of rumored regulatory action related to one of the Company's incinerators. We believe the issue is not meaningful to results and we would be willing to add to shares on pullbacks related to this. Stericycle's stock trades in the mid to high-颅��eens EBITDA range, but the company routinely purchases smaller competitors for just 3X-颅��X EBITDA. This accretion is a byproduct of Stericycle's competitive positioning and we believe it paves a multi-颅��ear runway for double-颅��igit growth.From David Rolfe (Trades, Portfolio)'s Wedgewood Partners first quarter 2014 commentary.
Also check out: David Rolfe Undervalued Stocks David Rolfe Top Growth Companies David Rolfe High Yield stocks, and Stocks that David Rolfe keeps buying
Currently 0.00/512345Rating: 0.0/5 (0 votes)
- [By Ben Levisohn]
Overvalued companies include MWI Veterinary (MWIV) and�Stericycle (SRCL), while companies with attractive valuations include Cardinal Health (CAH), Selected Medical (SEM). He’s not a fan of Intrexon (XON) but calls�Aratana (PETX) a “hidden gem.”
Top Life Sciences Stocks To Invest In Right Now: LKQ Corp (LKQ)
LKQ Corporation (LKQ) provides replacement parts, components and systems needed to repair vehicles (cars and trucks). The Company operates in four segments: Wholesale-North America, Wholesale-Europe, Self Service and Heavy-Duty Truck. Buyers of vehicle replacement products have the option to purchase from primarily five sources: new products produced by original equipment manufacturers (OEMs), which are known as OEM products; new products produced by companies other than the OEMs, which are sometimes referred to as aftermarket products; recycled products originally produced by OEMs, which it refers to as recycled products; used products that have been refurbished; and used products that have been remanufactured. October 1, 2011, it acquired Euro Car Parts Holdings Limited (ECP). On May 27, 2011, it acquired AkzoNobel Coatings Inc.'s paint distribution business consisting of 40 locations across the United States. In February 2012, the Company announced that it had acquired Pieces Automobiles Lecavalier IncEffective August 6, 2013, LKQ Corp acquired Premier Paints Ltd, a manufacturer of motor vehicle parts, form Iris Coatings Ltd, and concurrently, LKQ acquired Bee Bee Refinishing Supplies Halstead, JCA Coatings, Milton Keynes Paint & Equipment and Sinemaster Motor Factors Ltd.
The Company distributes a variety of products to collision and mechanical repair shops, including aftermarket collision and mechanical products, recycled collision and mechanical products, refurbished collision replacement products such as wheels, bumper covers and lights, and remanufactured engines. Collectively, it refers to its products as alternative parts. The Company is a provider of alternative vehicle collision replacement products, and a provider of alternative vehicle mechanical replacement products. Its sales, processing, and distribution facilities reach markets in the United States and Canada. In addition to its wholesale operations, it operates self service retail facilities that sell recycled automotiv! e products. The Company also sells recycled heavy-duty truck products and used heavy-duty trucks.
The Company obtains its aftermarket inventory from auto parts manufacturers and distributors based in the United States, Taiwan, Europe and China. The Company procures recycled automotive products mainly by purchasing salvage vehicles, typically severely damaged by collisions and primarily sold at salvage auctions or pools, and then dismantling and inventorying the parts. The refurbished and remanufactured products that it sells, such as wheels, bumper covers, lights and engines, originate from Companyparts from the salvage vehicles bought at auctions, parts received in trade at collision shops purchasing replacement products from the, and damaged parts bought through bulk purchases from core sales companies that collect damaged parts. The majority of our products and services are sold to collision repair shops, also known as body shops, and mechanical repair shops.
WHOLESALE AUTO PRODUCTS-NORTH AMERICA
The Company�� wholesale automobile product operations in North America are organized by geographic regions serving the United States and Canada that sell all four product types to collision and mechanical automobile repair businesses. As of December 31, 2011, these wholesale operations conducted business from more than 290 facilities. its aftermarket product operations may include a combination of sales, warehousing and distribution, and in many cases will be co-located with its refurbishing operations. Its salvage operation typically has processing, sales, distribution and administrative operations on site, indoor and outdoor storage areas, and include a warehouse with multiple bays to dismantle vehicles.
The Company�� 2011, sales included more than 86,000 stock keeping units (SKUs) of aftermarket collision products and repair materials for the models of domestic and foreign automobiles and light trucks. Its aftermarket product types consist of thos! e frequen! tly damaged in collisions, including automotive body panels, bumper covers and lights. The Company distributes paint and other materials used in repairing damaged vehicles, including sandpaper, abrasives, masking products and plastic filler. The paint and other materials distributed by the Company are purchased from numerous suppliers in the United States and Canada. Certain of these products are distributed under the brand Keystone. Platinum Plus is its exclusive brand offered in the Keystone product line of aftermarket products. The aftermarket products it distributes are purchased from independent manufacturers and distributors located primarily in the United States and Taiwan. The Company has business arrangements with manufacturers to produce its Platinum Plus products.
The Company�� recycled products include engines, transmissions, doors, front end assemblies, trunk lids, bumper assemblies, head and tail lamp assemblies and mirrors. Some insurance companies mandate that the recycled products must be of the same model year or newer as the vehicle being repaired. The Company procures recycled products for its wholesale operations by acquiring damaged or totaled vehicles. During the year ended December 31, 2011, LKQ acquired approximately 228,000 salvage vehicles for its wholesale recycled product operations. Vehicle processing for its wholesale recycled operations involves dismantling a salvage vehicle into recycled products that are ready for sale.
As of December 31, 2011, it operated 34 plastic bumper and bumper cover refurbishing plants, a chrome bumper plating plant, 15 wheel plants, one light refurbishing plant and four engine remanufacturing facilities. Most of its refurbished and remanufactured products are sold through its wholesale distribution channels. The balance is sold to retail automotive stores, wholesale distributors and through Internet sales. Its wholesale recycled product operations generate scrap metal and other materials that it sells to recyclers. T! he Compan! y has a distribution network of over 290 wholesale plants and warehouses across the United States and Canada, of which 50 function as hub or cross dock facilities.
WHOLESALE AUTO PRODUCTS-EUROPE
The Company�� European wholesale operating segment was formed in 2011 with its acquisition of ECP, the distributor of automotive aftermarket products. The Company operates 90 branches, supported by eight regional hubs and a national distribution center, which allows us to reach major markets within the United Kingdom. In 2011, it sold more than 121,000 SKUs of aftermarket products, primarily composed of mechanical aftermarket parts for the repair of vehicles five to 15 years old. Its products include electrical products, such as spark plugs and ignition coils, clutches and related parts, steering and suspension parts, and brake pads and sensors. The Company sells its products to over 32,000 professional repairers, including primarily independent mechanical repair shops and collision repair shops.
SELF SERVICE RETAIL PRODUCTS
The Company�� self service retail operations sell parts from older cars and light trucks directly to consumers. In addition to revenue from the sale of parts, core and scrap, it charges admission fee to access the property. Its self service facilities typically consist of a fenced or enclosed area of several acres with vehicles stored outdoors and a retail building through which customers are able to access the yard. As of December 31, 2011, it conducted our self service retail operations from 47 facilities in North America. Its self service auto recycling operations generate scrap metal, alloys and other materials that it sells to recyclers.
HEAVY-DUTY TRUCK PRODUCTS
As of December 31, 2011, it had a total of 18 facilities in the United States and Canada. Its inventory is comprised of used heavy- and medium-duty trucks, usually five years or older, which are purchased at salvage and truck auctions or direct! ly from i! nsurance companies or fleet operators. During 2011, it purchased approximately 6,000 vehicles. Depending on the condition of the vehicles, they may be dismantled for parts or resold as running vehicles. If certain mechanical parts are damaged, such as transmissions, it may remanufacture them and offer them to its customers. The vehicles that are acquired for resale are typically special purpose or vocational use trucks, such as those used for garbage pickup or cement delivery. If requested by the sellers of the vehicles, it provide an assurance that the vehicles will be sold to foreign buyers and exported to countries for use outside of the United States, or to domestic buyers after the vehicles have been reconditioned and modified for use other than their original purpose.
Advisors' Opinion:- [By Holly LaFon]
LKQ Corporation (LKQ) is the world's largest procurer and distributor of alternative and aftermarket collision replacement parts for automobiles and other vehicles. The Company has grown rapidly since its inception in 1998, by executing an expansion strategy that has included aggressive organic and inorganic investments. To date, LKQ's strategy has resulted in a business with unparalleled scale, at over $5 billion in revenues across three continents, compared with aftermarket and salvage parts competitors that routinely post less then $100 million in sales, usually with the largest footprints limited to regional geographies.
Top Life Sciences Stocks To Invest In Right Now: JinkoSolar Holding Company Limited(JKS)
JinkoSolar Holding Co., Ltd., together with its subsidiaries, engages in the manufacture and sale of solar power products in China and internationally. The company provides solar modules, silicon wafers and ingots, and solar cells, as well as processing services, including silicon wafer tolling services. It sells its products under the JinkoSolar brand name. The company?s customers include distributors, project developers, and system integrators. It trades its products under short-term contracts and by spot market sales. The company also produces accessory materials for solar power products, such as solar aluminum frame, solar junction box, aluminum materials windows, and other metal component parts. JinkoSolar Holding Co., Ltd. was founded in 2006 and is based in Shangrao, the People?s Republic of China.
Advisors' Opinion:- [By Wall Street Strategies]
Naturally the news is a big positive for the industry, with Chinese solar names like Yingli (YGE), Trina (TSL), Canadian Solar (CSIQ) -- which is actually Chinese despite its name -- JinkoSolar (JKS), JA Solar (JASO), and LDK Solar (LDK) each up more than 10% at midday. The Guggenheim Solar ETF (TAN), which tracks several global solar companies, was up 8%, breaking to a new 52-week high.
Top Life Sciences Stocks To Invest In Right Now: NK Lukoil OAO (LUKOY)
LUKOIL is a Russia-based integrated oil and gas company. The Company is engaged in the business of oil exploration, production, refining, marketing and distribution. The Company's exploration and production activity is located in Russia, and its main resource base is in Western Siberia. It owns modern refineries, gas processing and petrochemical plants located in Russia, Eastern and Western Europe. The Company�� petroleum products are sold in Russia, Eastern and Western Europe and United States. The Company operates in four business segments: exploration and production, refining, marketing and distribution, and chemicals and other business.
In January 2009, the Company acquired a 100% interest in Energoaktiv ZAO. In March 2009, the Company established a subsidiary, LUKOIL Overseas Holding GmbH. In Addition, in March 2009, LUKoil OAO increased its stake in TGK-8 OAO up to 60.21% from 31.38% previously held. In December 2009, the Company sold its 99.99% stake in Agentstvo LUKOM-A OOO. In February 2010, the Company established a research center, LUKOIL-Engineering OOO, which would be responsible for the research and engineering complex of the exploration and production business segment. The main production region of the Company is Western Siberia. LUKOIL is carrying out international exploration and production projects in Kazakhstan, Egypt, Azerbaijan, Uzbekistan, Saudi Arabia, Colombia, Venezuela, Cote d��voire, Ghana and Iraq.
LUKOIL owns oil refining capacity both in Russia and abroad. In Russia the Company owns four large refineries at Perm, Volgograd, Ukhta and Nizhny Novgorod. Total capacity of LUKOIL facilities in Russia is 44.7 million tons of oil per year. LUKOIL also has refineries in Ukraine, Bulgaria, Romania, and a 49% stake in ISAB refining complex (island of Sicily, Italy), with total capacity of 21.8 million tons per year.
Advisors' Opinion:- [By Dividend Growth Investor]
ConocoPhillips (COP) explores for, produces, transports, and markets crude oil, bitumen, natural gas, liquefied natural gas, and natural gas liquids on a worldwide basis. I am attracted to the above average yield on ConocoPhillips, in comparison to Exxon and Chevron. Unfortunately Chevron is already one of my highest weighted positions, which is why ConocoPhillips was the second US oil choice. I am building my position in the stock with this purchase. The company is extremely well run, has a history of disposing out of non-core assets such as Lukoil stock (LUKOY) and Kashagan Project, and sending cash to shareholders in the process. The company has increased dividends for 13 years in a row, and has managed to boost them by 15.10%/year over the past decade. Currently, the stock trades at 10.70 times earnings and yields 4.20%. Check my analysis of ConocoPhillips.
- [By Charles Sizemore]
Next on the list is French oil major Total SA (TOT). Total raised some eyebrows last month as discussions progressed to develop Russia�� massive shale fields in partnership with Lukoil (LUKOY). It appears that, despite the ongoing threat of sanctions from the United States, business is going on as usual in the real world.
Top Life Sciences Stocks To Invest In Right Now: Cell Therapeutics Inc (CTIC)
Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.
Pixuvri
As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.
OPAXIO
OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.
Tosedostat
In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.
Brostallicin
As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).
The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.
Advisors' Opinion:- [By John Udovich]
If you have not been watching the biotech sector lately, you should start paying attention as the sector along with small cap biotech stocks like Cell Therapeutics Inc (NASDAQ: CTIC), BIND Therapeutics Inc (NASDAQ: BIND) and TNI BioTech (OTCMKTS: TNIB) continue to produce a steady stream of good news for investors thanks to positive industry trends. Moreover, Ophthotech Corp (NASDAQ: OPHT), Foundation Medicine Inc (NASDAQ: FMI), Evoke Pharma and Fate Therapeutics Inc (NASDAQ: FATE) are this week's biotech IPOs that will no doubt be watched closely by Wall Street and industry observers in general. With that in mind, consider the following biotech news or recent articles about the industry and the small cap players in it:
- [By John Udovich]
Large and small cap cancer stocks Gilead Sciences, Inc (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG), Veracyte (NASDAQ: VCYT), Genomic Health, Inc (NASDAQ: GHDX), Cell Therapeutics Inc (NASDAQ: CTIC) and MetaStat Inc (OTCMKTS: MTST) have all been producing a steady stream of news lately for biotech investors looking for a way to cash in on the growth in development of�cancer treatments. Just consider the following news:
- [By John Udovich]
The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns�plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many�� planned biotech IPOs that have recently been announced publicly:
- [By Sean Williams]
Cell Therapeutics (NASDAQ: CTIC )
Certainly no discussion of companies with large accumulated deficits would be complete without discussing a biotechnology company. It's perfectly understandable to see a biotech, especially a clinical-stage one, run with an accumulated deficit, as it takes time and money to build up a drug pipeline. However, after multiple complete response letters (the equivalent of a rejection) by the Food and Drug Administration and years without an approved drug, Cell Therapeutics racked up an astounding $1.83 billion in accumulated deficits through the end of fiscal 2012. By comparison, that's nearly 56 times larger than its shareholder equity.�
Top Life Sciences Stocks To Invest In Right Now: Spectrum Brands Holdings Inc.(SPB)
Spectrum Brands Holdings, Inc., together with its subsidiaries, operates as a consumer products company worldwide. It offers consumer batteries, including alkaline and zinc carbon batteries, rechargeable batteries and chargers, and hearing aid batteries and other specialty batteries; pet supplies, such as aquatic equipment and supplies, dog and cat treats, small animal foods, clean up and training aids, health and grooming products, and beddings; and home and garden control products comprising household insect controls, insect repellents, and herbicides. The company also provides electric shaving and grooming devices; small appliances, including small kitchen appliances and home product appliances; electric personal care and styling devices; and portable lighting. Its sells its products through various trade channels, including retailers, wholesalers and distributors, hearing aid professionals, industrial distributors, and original equipment manufacturers primarily under t he Rayovac, Remington, Varta, George Foreman, Black & Decker, Toastmaster, Farberware, Tetra, Marineland, Nature?s Miracle, Dingo, 8-in-1, Littermaid, Spectracide, Cutter, Repel, Hot Shot, Black Flag, and TAT brands. The company was headquartered in Madison, Wisconsin. As of January 7, 2011, Spectrum Brands Holdings, Inc. operates as a subsidiary of Harbinger Group Inc.
Advisors' Opinion:- [By Ben Levisohn]
Shares of Energizer have jumped 15% to $112.37 at 10:24 a.m. today, while Spectrum Brands (SPB) has risen 1.4% to $76.88 and Kimberly Clark (KMB) has gained 1% to $112.14.
- [By Marc Bastow]
Consumer products manufacturer Spectrum Brands (SPB) raised its quarterly dividend 20% to 30 cents per share, payable on Mar. 18 to shareholders of record as of Feb. 19.
SPB Dividend Yield: 1.58%
Top Life Sciences Stocks To Invest In Right Now: Novartis AG (NVS)
Novartis AG, incorporated on February 29, 1996, provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company has five segments: Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals; vaccines and diagnostics, which include human vaccines and blood-testing diagnostics, and consumer health, which include over-the-counter medicines (OTC) and Animal Health. On April 8, 2011, the Company acquired the remaining non-controlling interest in Alcon, Inc. In December 2013, Alliance Pharma plc announced that its wholly owned subsidiary, Alliance Pharmaceuticals Limited, acquired all the United Kingdom and Republic of Ireland (ROI) rights to Lypsyl from Novartis AG.
In April 2011, Novartis sells global rights to Elidel, a medicine to treat atopic dermatitis to Meda. In March 2011, Novartis completes acquisition of majority stake in Zhejiang Tianyuan vaccines company in China. In March 2011, the Company acquired Genoptix, Inc. In October 2011, Novartis discontinues development of AGO178 for depressive disorder. In December 2011, the Company discontinues development of PRT128 for acute coronary syndrome and chronic coronary heart disease, and SMC021 for osteoporosis and osteoarthritis. In April 2011, Alcon's portfolio of generic ophthalmic medicines sold through its Falcon business unit primarily in the United States.
Pharmaceuticals Division
The Company�� Pharmaceuticals Division researches, develops, manufactures, distributes and sells patented prescription medicines in the therapeutic areas, such as Oncol! ogy; Primary Care, consisting of Primary Care medicines and Established Medicines, and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The Pharmaceuticals Division is organized into global business franchises responsible for the commercialization of various products, as well as Novartis Oncology, a business unit responsible for the global development and commercialization of oncology products, and Novartis Molecular Diagnostics, a business responsible for the development and commercialization of diagnostic tests and services related to its pharmaceuticals portfolio and therapeutic areas.
The Company�� Oncology products include Afinitor/Votubia, Exjade, Sandostatin SC/Sandostatin LAR , Femara , Zometa, Tasigna and Gleevec/Glivec. Gleevec/Glivec, which is a signal transduction inhibitor approved to treat patients with certain forms of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Tasigna is a signal transduction inhibitor of the tyrosine kinase activity of Bcr-Abl, KIT+ and the PDGF-receptor. Zometa is a treatment to reduce or delay skeletal-related events (SREs), including pathologic fracture, spinal cord compression, and/or requirement of radiation therapy or surgery to bone, in patients with bone metastases (cancer that has spread to the bones) from solid tumors and multiple myeloma. Femara is a once-daily oral aromatase inhibitor for the treatment of early stage or advanced breast cancer in postmenopausal women. Sandostatin SC/Sandostatin LAR is indicated for the treatment of patients with acromegaly, a chronic disease caused by over-secretion of pituitary growth hormone in adults. Sandostatin is also indicated for the treatment of patients with certain symptoms associated with carcinoid tumors and other types of gastrointestinal and pancreatic neuroendocrine tumors. Exjade is an oral iron chelator approved for the treatment of chronic iron overload due to blood transfusions in patients over ! two years! of age who have a range of underlying anemias. Patients with congenital and acquired chronic anemia, such as thalassemia, sickle cell disease and myelodysplastic syndromes, require transfusions, which puts them at risk of iron overload. Afinitor/Votubia is an oral inhibitor of the mTOR pathway.
The Company�� Primary Care products include Arcapta Neohaler/Onbrez Breezhaler, Diovan, Exforge, Tekturna/Rasilez, Galvus, Reclast/Aclasta, Voltaren/Cataflam, Ritalin, Ritalin LA, Focalin and Focalin XR. Its Specialty Care products include Lucentis, Gilenya, Exelon, Extavia and Comtan, and Stalevo. Its Integrated Hospital Care include Zortress/Certican, Ilaris, Neoral and Myfortic.The Company�� Critical Care products include Xolair and Tobi Podhaler. As of December 31, 2011, the products under development includes ACZ885, which is being investigated for the secondary prevention of cardiovascular events and for the treatment of Diabetes Mellitus; AEB071 (sotrastaurin) is a low molecular weight, selective inhibitor of protein kinase-C (PKC); AFQ056 (mavoglurant) is a metabotropic glutamate receptor 5 (mGluR5) antagonist in Phase II development for the treatment of Parkinson's disease levodopa-induced dyskinesia; AIN457 (secukinumab) is a human monoclonal antibody neutralizing interleukin-17A, a key pro-inflammatory cytokine expressed by TH17 cells and other types of white blood cells; BAF312 is an oral, second-generation sphingosine 1-phosphate receptor modulator in Phase II development for relapsing-remitting multiple sclerosis; DEB025 (alisporivir) is a cyclophilin inhibitor for the treatment of Hepatitis C virus infection (HCV); Gileny a line treatment for relapsing forms of MS; Exjade (deferasirox) is an oral iron chelator in development for use in patients with non-transfusion-dependent thalassemia (NTDT); INC424 (ruxolitinib) is an investigational Janus kinase (JAK) inhibitor, and Zortress/Certican (everolimus) is an mTOR inhibitor with immune/non-immune cell proliferation inhibition being d! eveloped ! for prevention of solid organ transplant rejection.
Alcon Division
The Company�� Alcon Division discovers, develops, manufactures, distributes and sells eye care products. Alcon is engaged in eye care with product offerings in Surgical, Ophthalmic Pharmaceuticals and Vision Care. In Surgical, Alcon develops, manufactures, distributes and sells ophthalmic surgical equipment, instruments, disposable products and intraocular lenses. In Pharmaceutical, Alcon discovers, develops, manufactures, distributes and sells medicines to treat chronic and acute diseases of the eye, as well as over-the-counter medicines for the eye. In Vision Care, Alcon develops, manufactures, distributes and sells contact lenses and lens care products.
Alcon's Surgical portfolio includes the Infiniti vision system for cataract procedures, the Constellation vision system for retinal operations, and the AcrySof family of intraocular lenses (IOLs), including the AcrySof IQ, AcrySof IQ ReSTOR, AcrySof IQ Toric and AcrySof IQ ReSTOR Toric IOLs. During the year ended December 31, 2011, its Alcon Division launched the LenSx femtosecond laser, a technology in cataract surgery, which increases the precision and reproductibility for corneal incisions, capsulorhexis and lens fragmentation steps of the procedure. In addition, Alcon provides advanced viscoelastics, surgical solutions, surgical packs and other disposable products for cataract and vitreoretinal surgery.
Alcon Division's Ophthalmic Pharmaceuticals business combines Alcon's range of pharmaceuticals with selected ophthalmic products (excluding Lucentis) previously marketed by the Novartis Pharmaceuticals Division. The products treat chronic and acute diseases of the eye including glaucoma and allergies, as well as anti-infective/anti-inflammatory and dry eye treatments. our Alcon Division's Ophthalmic Pharmaceuticals portfolio include Travatan Z solution and DuoTrav solution for the treatment of elevated intraocular pressure associ! ated with! glaucoma; Vigamox solution for bacterial conjunctivitis; Pataday solution for ocular itching associated with allergic conjunctivitis; and Nevanac suspension for eye inflammation following cataract surgery. Alcon launched a number of products during 2011, including Dailies Total 1 lenses, Opti-Free EverMoist Multi Purpose Disinfecting Solution, LenSx laser, AcrySof IQ ReSTOR Toric lens, AcrySof IQ Toric T6-T9 lens, Travatan BAK-free solution, DuoTrav BAK-free solution, Moxeza solution and Systane Balance eye drops.
Sandoz Division
The Company�� Sandoz Division is a global generic pharmaceuticals company that develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical and biotechnological active substances, which are not protected by valid and enforceable third-party patents. The Sandoz Division has activities in Retail Generics, Anti-Infectives, and Biopharmaceuticals and Oncology Injectables. In Retail Generics, Sandoz develops, manufactures and markets active ingredients and finished dosage forms of pharmaceuticals, as well as supplying active ingredients to third parties. In Anti-Infectives, Sandoz develops and manufactures active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by retail generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products (biosimilars or follow-on biologics) and sells biotech manufacturing services to other companies.
In Oncology Injectables, Sandoz develops, manufactures and markets primarily cytotoxic products for the hospital market. During 2011, the Company launched generic docetaxel (Taxotere), higher-strength generic amlodipine-benazepril (Lotrel), generic meropenem (Merem) injection, and the formation of a women's health portfolio with generic Seasonale, Nordette, Yaz and Yasmin. The product launched in various European countries included generic docetaxel, ge! neric ana! strazole (Arimidex), and valsartan/covalsartan (an early entry generic version of Novartis Pharmaceuticals' Diovan/Co-Diovan).
Vaccines and Diagnostics Division
The Company�� Vaccines and Diagnostics Division researches, develops, manufactures, distributes and sells preventive vaccines and diagnostic tools. Novartis Vaccines is a global developer and manufacturer of human vaccines. Novartis Diagnostics is a blood testing and molecular diagnostics business dedicated to preventing the spread of infectious diseases through blood-screening tools that protect the world's blood supply. Novartis Vaccines' products include influenza, meningococcal, pediatric, adult and travel vaccines.
The Company�� influenza vaccines include Agrippal, Fluad, Fluvirin and Optaflu. Its Meningococcal Vaccines includes Menjugate and Menveo. Its travel vaccines include Encepur Children, Encepur Adults, Ixiaro and Rabipur/Rabavert. Its Pediatric Vaccines include Polioral and Quinvaxem.
Consumer Health
Consumer Health consists of two Divisions: OTC (over-the-counter medicines) and Animal Health. Each has its own research, development, manufacturing, distribution and selling capabilities. OTC offers readily available consumer medicine. Animal Health provides veterinary products for farm and companion animals.
OTC (over-the-counter medicines) offers products for the treatment and prevention of common medical conditions and ailments. OTC business focuses on a group of global brands in product categories that include treatments for cough/cold/respiratory (Triaminic, Otrivin, TheraFlu/NeoCitran), pain relief (Excedrin, Voltaren), digestive health (Benefiber, Prevacid24HR, Pantoloc Control), dermatology (Lamisil, Fenistil), and smoking cessation (Habitrol/Nicotinell).
Animal Health offers products and services focusing on both companion and farm animals (including cultivated fish). Key products for companion animals include Atopica (atopic dermatitis manageme! nt), Dera! maxx and Onsior (pain relief), Fortekor (heart failure in dogs, chronic renal insufficiency in cats), and Sentinel/Milbemax/Interceptor (intestinal parasite control and heartworm prevention), while farm animal products include the therapeutic anti-infective Denagard, an antimicrobial used to treat and control bacteria in swine, CLiK, an insect growth regulator used to control blowfly strike in sheep, cattle vaccines used to prevent respiratory and reproductive diseases in beef and dairy cattle, and Zolvix, a sheep drench representing the new sheep anthelmintic class. Aquaculture products include vaccines and treatments mainly used in salmon farming.
Advisors' Opinion:- [By Philip Springer]
This was a big week for the global pharmaceutical industry. First, rumors of one deal suggested a possible return to the industry’s old self-destructive ways. But then two other transactions were announced that signaled continuation of a newer trend that’s much healthier for shareholders.
On Monday, it was reported that New York-based Pfizer Inc. (NYSE: PFE) had been in talks to acquire AstraZeneca PLC (NYSE: AZN), headquartered in London, for over $100 billion. The companies apparently broke off the discussions.
If such a transaction were to occur, it would be the latest in a long series of megamergers that characterized the corporate strategies of Pfizer, Swiss drug giant Novartis AG (NYSE: NVS) and others in the 1990s and 2000s. Back then, the aim was to acquire rivals in multibillion-dollar deals that broadened the buyers’ businesses to cover more diseases and new health-care areas.
The catalyst for this buying binge was the so-called patent cliff, in which some of the sector’s biggest drugs faced the loss of patents that protected them from competition, resulting in reduced revenues and earnings.
Since then, however, the patent cliff problem has waned because many of those patent expirations have already occurred. And the bigger, combined companies generally have come up short on development of new blockbuster drugs. Also, excessive diversification has brought weak competitive positions in some niches.
But the current industry trend is for companies to focus more on their core strengths instead of diversifying. Pfizer, Bristol-Myers Squibb (NYSE: BMY), Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) have made such moves over the last few years in order to focus on what they consider higher-growth prospects.
Tuesday brought more of the same. Novartis and UK-based GlaxoSmithKline (NYSE: GSK) announced more than $20 billion in deals. Novartis is to sell its animal-drugs busi - [By Charles Rice, Associate Editor - November 6, 2013 Money Morning]
Novartis AG (NYSE ADR: NVS) is the largest pharmaceutical company in Russia. Its subsidiary Sandoz is one of the largest generics manufacturers in the world.
No comments:
Post a Comment